Abstract: The present invention provides for compositions and methods for administering one or more UDP compound, alone or in combination with another hematopoietic progenitor cell mobilizing compound (for example, but not limited to G-CSF), to mobilize hematopoietic progenitor cells for transplant or other purposes. The methods of the invention may be particularly advantageous as applied to improve the stem cell yield in so-called “poor mobilizing” patients.

Abstract: A three-dimensional cell culture scaffold and preparation method thereof. The preparation method comprises the following steps: designing, according to a shape of a cell culture device, a shape of the three-dimensional cell culture scaffold; printing once by a 3D printer to form the three-dimensional cell culture scaffold; performing a surface treatment, by a surface treating agent, on the three-dimensional cell culture scaffold manufactured by 3D printing to obtain a resultant three-dimensional cell culture scaffold. By adopting a three-dimensional printing technology to manufacture a three-dimensional fibrous cell culture scaffold having a three-dimensional fibrous network structure, raw materials and a manufacturing time can be saved, reducing production costs, increasing production efficiency, decreasing power consumption, preventing a flaw in the conventional manufacturing technique, and facilitating large-scale intelligent manufacturing.

Abstract: The present invention is directed to an apparatus for monitoring a cell culture comprising a) one or more infrared sensors positioned adjacent to a cell culture, the one or more infrared sensors capable of recording an infrared heat signal from the cell culture; b) a power source in electrical communication with the one or more infrared sensors; c) a data storage and computation device configured to receive and analyze the infrared heat signal from the one or more infrared sensors; and d) a transmitter device in electrical communication with the storage and computation device; wherein the apparatus monitors the pattern of heat production in the cell culture. The present invention is also directed to methods for monitoring and analyzing the metabolic activity of cells using the above apparatus.

Abstract: The present invention relates to a liquid composition soluble in water or other polar substance and its use for vehicle cleansing and care, in particular for all the treatments provided in the washing steps of vehicles. The composition comprises at least one active enzymatic component.

Abstract: The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount.

Abstract: The invention relates to methods for predicting the in vivo nephrotoxicity of a drug substance, in particular a nucleic acid molecule such as a siRNA or an antisense oligonucleotide using an in vitro cell based assay measuring the levels of extracellular EGF as toxicity biomarker, potentially in combination with other biomarkers like ATP and KIM-1.

Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.

Abstract: Methods are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation and for obtaining desired cells from cryopreserved and fresh bone marrow.

Abstract: The present invention provides a method of stably integrating a DNA sequence of interest into a target genomic DNA sequence of a host cell, wherein the target genomic DNA sequence comprises a nucleotide sequence that is at least 80% homologous to the sequence as set forth in SEQ ID NO:1, as well as a kit for use in said method. Also provided is a method of generating a circular DNA construct essentially consisting of a DNA sequence of interest and a nucleotide sequence that is at least 80% homologous to the sequence as set forth in SEQ ID NO:3.

Abstract: Provided herein are novel Lactobacillus fermentum strains, NRRL B-67059 or NRRL B-67060, compositions containing the NRRL B-67059 or NRRL B-67060 strains, and fermented dairy products and bioactive compounds prepared using the NRRL B-67059 or NRRL B-67060 strains. Also provided are methods of modulating the immune system of a subject.

Abstract: Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment, the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes.

Abstract: Biological indicators may be improperly activated. The disclosed subject matter is directed to methods of confirming that a biological indicator having an ampule containing a growth medium has been properly activated such that it may be assayed. The methods may include the steps of measuring a first fluorescence intensity of the biological indicator, heating the biological indicator; quenching the fluorescence intensity of the biological indicator from the first fluorescence intensity to a second fluorescence intensity, measuring the second fluorescence intensity; comparing the second fluorescence intensity and first fluorescence intensity to obtain a comparison value; and determining that the comparison value corresponds to a quenching metric of the liquid growth medium.

Abstract: The present invention features, inter alia, pharmaceutical compositions and their use in the preparation of a medicament (e.g., a medicament for inflammation, such as an inflammatory lung disease) or in a therapeutic regimen. The compositions can include at least two active agents: a first agent that inhibits PDE4 (e.g., roflumilast) and a second active agent that inhibits the expression or activity of one or more PDE4B variants (e.g., PDE4B2). The compositions and methods will attenuate an unwanted up-regulation of a PDE4B (e.g., PDE4B2) and may thereby improve treatment with the first agent (e.g., roflumilast). For example, the second agent may improve the efficacy of the first agent, decrease the effective dose of the first agent, ameliorate the tolerance to the first agent that would otherwise develop (e.g., in patients with COPD exacerbation), reduce unwanted side effects caused by the first agent, or otherwise improve treatment regimes including a PDE4 inhibitor.

Abstract: Methods, systems, and devices are disclosed for in vivo production or biosynthesis of metabolites in foreign cells using the combination of (i) one or more ferredoxin dependent enzyme(s) and (ii) a ferredoxin (Fd)/ferredoxin-NADP+ reductase (FNR) system. The ferredoxin dependent enzymes and the Fd/FNR system are from the same species or from a different but matching species.

Abstract: The present invention relates to a method for producing yeast. It relates in particular to a method for producing biological yeast, comprising the use of substrates of biological origin, in particular a biological substrate which makes it possible to supplement the nutritional requirements in the yeast in terms of phosphorus. The method of the present invention makes it possible to obtain biological yeast and biological yeast extracts in accordance with European Union Regulation (EC) 834/2007. According to the invention, the phosphorus-rich biological composition is obtained by hydrolysis and solubilization of at least one plant substrate of biological origin comprising from 2 to 18 g of phosphorus per kg of product, 60% to 80% of which is in the form of phytic acid. The preferred substrate according to the invention is wheat bran.

Abstract: Provided herein is a process for producing a fermentation product from a lignocellulosic feedstock. The process comprises soaking a lignocellulosic feedstock in an aqueous solution to produce a soaked feedstock. The soaked feedstock is at least partially dewatered and the at least partially dewatered feedstock is subjected to pretreating. The pretreatment chemical is sulfur dioxide, sulfurous acid or a combination thereof and can be added to the process at any stage prior to and/or during pretreatment. The pretreated feedstock composition is fed to an enzymatic hydrolysis conducted at a temperature that is higher than 58° C. The cellulose in the pretreated feedstock composition is hydrolyzed with cellulase enzymes in the presence of the dissolved solids to produce glucose. The glucose is fermented to produce the fermentation product.

Abstract: The present invention relates to a method for generating neuronal and muscular cells from pluripotent stem cells.

Abstract: Described our medical compositions and methods including a particulate extracellular matrix tissue in admixture with sugar. Such medical compositions, in dried forms, can demonstrate enhanced rehydration properties. Medical compositions and products as described herein find particular use in treating diseased and/or damaged tissue, such as wound repair. Related methods of manufacture and use are also described.

Abstract: Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of Embigin to a recipient subject and can also optionally include administering hematopoietic stem/progenitor cells to the subject. Another method involves administering an inhibitor of Embigin to a donor prior to harvest of hematopoietic stem/progenitor cells. Pharmaceutical compositions relating to the methods are also described.

Abstract: The present invention relates to methods and apparatus for detecting one or more pathogens in one or more biological samples. The biological sample may be a food sample, a sample of a body fluid, a cell suspension, water, or a combination thereof. The present invention relates also to methods of diagnosing or predicting a disease in an individual.